Open-Capsule Budesonide for Refractory Celiac Disease.
OBJECTIVE
Refractory celiac disease (RCD) is a rare condition often associated with poor prognosis. Various immunosuppressive medications (IMs) have been used with modest success. We describe outcomes in patients treated with open-capsule budesonide (OB), including those for whom IM treatment failed.


METHODS
We identified RCD patients treated with OB at Mayo Clinic, Rochester, Minnesota from 2003 to 2015. Demographic, serologic, and clinical variables were analyzed.


RESULTS
We identified 57 patients who received OB for suspected RCD. Based on clonal T-cell receptor gamma gene rearrangement or aberrant phenotype of intraepithelial lymphocytes (IELs), 13 patients (23%) were classified as having RCD-2 and 43 (75%) as RCD-1. In one patient (2%) TCR gene rearrangement status was unknown. Most patients were women (69%), mean (s.d.) age was 60.5 (3.5) years and body mass index was 28.4 (4.5) kg/m2. The majority had diarrhea (72%), with median of 6 bowel movements per day (range, 4-25). IM treatment (azathioprine, systemic corticosteroids, or regular budesonide) had failed in nearly half. Twenty-four patients (42%) had anemia and 12 (21%) had hypoalbuminemia. All had Marsh 3 lesions on biopsy: 3a (19%), 3b (46%), and 3c (35%). After OB therapy, the majority had clinical (92%) and histologic (89%) improvement. Follow-up biopsy in 7 out of 13 patients with RCD-2 (53%) showed an absence of clonal TCR gamma gene rearrangement/aberrant IEL phenotype previously seen. On follow-up, 2 patients (4%) died of enteropathy-associated T-cell lymphoma.


CONCLUSIONS
Most patients with RCD show clinical and histopathologic improvement with OB therapy, including those with failure of IMs. OB is a promising therapeutic option for management of RCD.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Saurabh S
SS
Mukewar
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Ayush
A
Sharma
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Alberto
A
Rubio-Tapia
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Tsung-Teh
TT
Wu
Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Bana
B
Jabri
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Joseph A
JA
Murray
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D019819:Budesonide / Q000008:administration & dosage*; D017252:CD3 Complex / Q000032:analysis; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D002214:Capsules; D002446:Celiac Disease / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D005260:Female; D015329:Gene Rearrangement, T-Lymphocyte; D019672:Genes, T-Cell Receptor; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D012189:Retrospective Studies; D013601:T-Lymphocytes / Q000737:chemistry*
D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D002214:Capsules; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D019819:Budesonide